SCHEMBL14633591

SCHEMBL14633591

Cc1ccc(Nc2ncc(-c3n[nH]c4c(Cl)cccc34)c(N)n2)cc1S(C)(=O)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
PKM P14618 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
CHEK1 O14757 1/20 0.37
FLT3 P36888 1/20 0.37
PLK3 Q9H4B4 1/20 0.37
WEE1 P30291 3/20 0.36
RIPK2 O43353 4/20 0.36
NOD2 Q9HC29 4/20 0.36
ACVR1 Q04771 3/20 0.36
KDR P35968 1/20 0.36
ALK Q9UM73 1/20 0.36
EPHB4 P54760 1/20 0.35
ABCB11 O95342 1/20 0.35
SGK1 O00141 1/20 0.35
JAK1 P23458 1/20 0.35
JAK3 P52333 1/20 0.35
CSNK1A1 P48729 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2468378 0.90 CDK1 (0.39) NPC1RAB9AKMT2AFLT3KDR
SCHEMBL2467099 0.86 GRM4 (0.40) WEE1RIPK2NOD2ACVR1KDR
SCHEMBL14634241 0.86 KDR (0.40) MEN1NPC1PKMRAB9AKMT2A
SCHEMBL14633720 0.84 CDK2 (0.39) FLT3KDRALKABCB11SGK1
SCHEMBL14634243 0.83 SGK1 (0.40) CHEK1ABCB11SGK1JAK1JAK3
SCHEMBL14633971 0.83 SGK1 (0.39) CHEK1FLT3KDRALKABCB11
SCHEMBL14634281 0.83 CDK1 (0.39) FLT3KDRALKABCB11SGK1
SCHEMBL2466308 0.82 GRM4 (0.41) CHEK1FLT3KDRALKABCB11
SCHEMBL2472742 0.81 JAK2 (0.40) FLT3KDRALKABCB11SGK1
SCHEMBL2468759 0.80 NTRK1 (0.44) CHEK1FLT3RIPK2KDRALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K20 MEN1 2485/4885NPC1 2912/4885PKM 1088/4885
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS CDK2, MAP3K19, MAP3K1 MEN1 2580/4885NPC1 3580/4885PKM 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.